title: Treatment with IGF-I peptides improves function of the remnant gut following small bowel resection in rats.
abstract: The effects of 7 days' s.c. infusion of 111-700 micrograms/day IGF-I on gut growth and absorptive function were examined in growing rats following removal of 70 or 80% of the jejuno-ileum, and compared with the responses to the analogues, LR3IGF-I and des(1-3)IGF-I, which bind poorly to IGF binding proteins. Administration of 278 micrograms/day IGF-I, LR3IGF-I or des(1-3)IGF-I following 70% jejuno-ileal resection significantly attenuated malabsorption of fat and nitrogen. Responses in rats with 80% resection were less substantial, but a dose-responsive reduction in malabsorption was apparent with LR3IGF-I. Both IGF-I and LR3IGF-I were shown to increase body weight gain and food conversion efficiency in a dose-dependent manner following 80% jejuno-ileal resection. Total gut weight was increased by up to 21%, due predominantly to increased weight of the stomach and proximal small bowel, with the latter effect attributable at least in part to an increased bowel length. LR3IGF-I was more potent than IGF-I at stimulating body weight gain and food conversion efficiency, but its potency advantage on gut absorptive function and small intestinal re-growth was less marked. We conclude that administration of IGF-I peptides improves gastro-intestinal absorptive function following partial gut resection, most likely reflecting, at least in part, an increase in gut absorptive surface area.
authors: Cooperative Research Center for Tissue Growth and Repair, North Adelaide, Australia.
authors: A B
authors: AB
authors: Lemmey
authors: F J
authors: FJ
authors: Ballard
authors: A A
authors: AA
authors: Martin
authors: F M
authors: FM
authors: Tomas
authors: G S
authors: GS
authors: Howarth
authors: L C
authors: LC
authors: Read
mesh_terms: D000222:Adaptation, Physiological / Q000187:drug effects; D000595:Amino Acid Sequence; D000818:Animals; D004041:Dietary Fats / Q000493:pharmacokinetics; D004195:Disease Models, Animal; D007334:Insulin-Like Growth Factor I / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects; D007421:Intestine, Small / Q000187:drug effects* / Q000502:physiology / Q000601:surgery; D008297:Male; D008969:Molecular Sequence Data; D009584:Nitrogen / Q000493:pharmacokinetics; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D012778:Short Bowel Syndrome / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
chemical_list: D004041:Dietary Fats; D010446:Peptide Fragments; D011994:Recombinant Proteins; C058957:insulin-like growth factor 1, des-(1-3)-; D007334:Insulin-Like Growth Factor I; D009584:Nitrogen